OBSITI

The primary objective of the ObsITI study is to evaluate and document data on the success rate of ITI in prospective and retrospective haemophilia A patients with newly developed or already existing FVIIIinhibitors, including patients with risk factors associated with a poor ITI prognosis, and those with prior ITI failure. It is recommended to treat patients according to the Bonn protocol... The Observational Immune Tolerance Induction (ObsITI) research program is an international open-label, uncontrolled, non-interventional, multi-centre observational program (ClinicalTrials.gov NCT 02207894) initiated by the the Paediatric Centre of the Johann Wolfgang-Goethe University Frankfurt, and continued by the Haemophilia Centre Rhine-Main (HZRM), Frankfurt-Mörfelden, Germany. The study started in 2005 and has a retrospective and a prospective arm. Data from patients, who currently undergo ITI or have undergone ITI will be collected in this study. The ITI outcome will be correlated to..

Registration numbers: HRB 91474 (W)

Primary location: Frankfurt Germany